Linaclotide Tablets

Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of linaclotide tablets in China. Welcome to wholesale bulk high quality linaclotide tablets for sale here from our factory. Good service and reasonable price are available.

Linaclotide Tablets represent an orally administered solid dosage form specifically engineered to provide a accurately composed peptide in a manner that ensures stability and ease of use for patients. This finished pharmaceutical product employs sophisticated production methods to guarantee uniform quality, dependable therapeutic effect, and site-specific release within the intestinal tract.

Linaclotide COA

 

 

1.Differences in Mechanism of Action

The core analgesic mechanism of nonsteroidal anti-inflammatory drugs (NSAIDs) widely used in clinical practice, such as ibuprofen, is to inhibit the activity of cyclooxygenase (COX) throughout the body, thereby reducing the synthesis of prostaglandins, a key inflammatory mediator. Prostaglandins are the core substances that mediate pain and inflammatory responses; By blocking its generation, it can not only directly block the transmission of pain signals to the central nervous system to achieve systemic analgesia, but also exert significant anti-inflammatory effects to alleviate pain stimuli from the source of inflammation, with its target covering various tissues and organs throughout the body.

In contrast, the mechanism of action of linaclotide tablets are highly localized. This drug does not enter the bloodstream and only acts on the guanylate cyclase C (GC-C) receptor on the surface of intestinal epithelial cells. It inhibits excessive contraction of intestinal smooth muscles and softens feces by generating cyclic guanosine monophosphate (cGMP), reducing intestinal wall tension and decreasing intestinal mucosal sensitivity. It only regulates the local pathological state of the intestine.

2.Differences in Indicated Types of Abdominal Pain

The application scope of other pain relieving drugs may be far beyond that of benazepril, and the above-mentioned ibuprofen is one of the preferred symptomatic drugs for clinical treatment of various abdominal pain symptoms. It can effectively alleviate various abdominal pain related to inflammation or injury, including inflammatory abdominal pain caused by infectious gastroenteritis, menstrual abdominal pain caused by primary dysmenorrhea or endometriosis, traumatic dull pain after abdominal surgery, and involvement pain caused by inflammatory diseases such as cholecystitis or appendicitis.

At the same time, it can also relieve non abdominal pain such as headaches, toothache, and joint pain.
In contrast, the analgesic range of linaclotide is very specialized and suitable for spastic abdominal pain caused by constipation predominant irritable bowel syndrome (IBS-C), which must be accompanied by symptoms of intestinal dysfunction such as constipation and bloating.

 

 

3.Differences in Efficacy Characteristics

The therapeutic advantage of linaclotide lies in its symptom-and-root-cause dual-targeting mechanism. Although it has a relatively slower onset of action, typically requiring 2 to 4 days of continuous medication to achieve stable relief of abdominal pain, the drug not only effectively alleviates abdominal pain but also concurrently addresses the underlying issues of intestinal dysfunction such as constipation and bloating. By acting locally in the intestines to regulate smooth muscle function and nerve sensitivity, linaclotide enables sustained symptom relief with a low recurrence rate after treatment discontinuation. This regulatory approach that targets the underlying causes endows it with unique long-term management value in treating specific functional bowel disorders such as irritable bowel syndrome with constipation (IBS-C).

4.Differences in Adverse Reactions and Contraindications

The adverse reactions of other analgesics, such as ibuprofen are mainly systemic effects, which are closely related to the dosage and duration of medication. Short-term administration of conventional doses may cause gastrointestinal irritation symptoms such as stomachache, nausea and acid reflux; long-term or excessive use will significantly increase the risk of gastric ulcer and gastrointestinal bleeding, and may also cause damage to liver and kidney functions, while inhibiting platelet aggregation and affecting blood coagulation function. The range of contraindicated populations for ibuprofen is also wider, including patients with gastric ulcer and duodenal ulcer, those with severe hepatic and renal insufficiency, patients with coagulation dysfunction, individuals allergic to non-steroidal anti-inflammatory drugs, as well as in the third trimester of pregnancy.

In contrast, the adverse reactions of linaclotide tablets are mainly local intestinal reactions, with mild diarrhea being the most common, which usually occurs in the early stage of treatment and can be gradually tolerated, almost without causing systemic side effects. Its contraindicated populations are only patients with mechanical gastrointestinal obstruction, children under 6 years old, and individuals allergic to the drug ingredients, with much fewer restrictions on applicable populations compared with ibuprofen.

Early Scientific Foundations in the United States (1980s–1990s)

The foundational research for Linaclotide was primarily conducted at academic institutions in the United States. The University of Texas Health Science Center at Houston, along with other research centers, elucidated its critical mechanisms. Key research in the 1990s, funded by the National Institutes of Health, laid the groundwork for the rational design of a synthetic agonist during this phase.

Peptide Engineering and Clinical Development (Late 1990s–Mid‑2000s)

In the late 1990s, the biotechnology company Microbia, based in Cambridge, Massachusetts, entered the drug design stage and later became Ironwood Pharmaceuticals, leading the field. Researchers at Ironwood Pharmaceuticals introduced multiple disulfide bonds to mimic the active structure of natural enterotoxins while conferring stability against enzymatic degradation in the gut. Extensive in vitro and animal studies conducted at facilities in the Boston area confirmed the efficacy of the drug candidate. During this period, Microbia (Ironwood Pharmaceuticals) transformed a scientific concept into a viable preclinical candidate.

Clinical Development, Formulation Innovation, and Regulatory Approval (Mid‑2000s–2012)

The final stage of development focused on translating the peptide into a safe and effective human therapeutic, particularly in tablet form. A significant clinical and formulation development partnership was established between Ironwood Pharmaceuticals and New York‑based Forest Laboratories. Pivotal Phase III clinical trials were conducted at multiple research centers across North America and Europe in the late 2000s to evaluate the drug's efficacy and safety. Following successful trials, New Drug Applications were submitted to regulatory authorities. In 2012, the U.S. Food and Drug Administration (FDA) in Silver Spring, Maryland, approved Linaclotide Tablets, marking their successful transition from laboratory research to a marketed pharmaceutical product.

01

Manufacturing Scalability

The established synthetic and purification protocols-primarily relying on solid-phase peptide synthesis (SPPS) and reverse-phase high-performance liquid chromatography (RP-HPLC)-ensure highly reproducible and consistent large-scale production. This standardized process enables efficient commercial manufacturing while meeting stringent pharmaceutical quality requirements for purity, potency, and batch-to-batch uniformity.

02

Stability‑Engineered Design

The enteric-coated tablet formulation is specifically engineered to protect the acid-sensitive peptide from degradation in the stomach's acidic environment. This design ensures the peptide remains intact through the upper gastrointestinal tract and is released only in the neutral-to-alkaline conditions of the small intestine, thereby delivering the active ingredient precisely to its site of action-the intestinal lumen, where the GC-C receptors are located.

Linaclotide represent a sophisticated pharmaceutical achievement that integrates precision peptide synthesis with advanced tablet manufacturing. Their production process begins with robust solid-phase peptide synthesis, followed by high-purity purification and lyophilization of the active ingredient. The formulation is then engineered into an enteric-coated tablet through controlled granulation, compression, and specialized film-coating, ensuring protection of the peptide from gastric degradation and targeted release in the intestine. This manufacturing approach not only ensures stability and reproducibility but also exemplifies how modern pharmaceutical technology can translate complex peptide therapeutics into reliable, patient-ready oral dosage forms. Ongoing improvements in production efficiency and quality control continue to enhance the tablet's role as a key therapy in digestive health management.

Hot Tags: linaclotide tablets, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale